Two index cases of living-related donor renal allografts patients developed C4d-negative rejection. Both cases had negative cytotoxic crossmatch and negative flow crossmatch before transplantation. The serum creatinine levels are shown in i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 1 0 ( 2 0 1 6 ) 1 5 -2 1
Introduction
The presence of C4d sub-endothelial deposition has been considered a major diagnostic element of antibody-mediated rejection (ABMR) after renal transplantation. More than 60% of late antibody mediated rejection (ABMR) is C4d negative. 1 Particularly important for the Indian setting is the practice of not routinely measuring the DSA by single antigen bead (SAB) assay at the time of graft biopsy done for evaluating graft dysfunction, as is done in western countries. Table 1 . Both cases experienced augmented anti-T cell therapy (Intravenous methyl prednisolone) at the time of rejection, which failed to improve renal function. Meantime, our HLA lab identified circulating anti-class I and/or II HLA antibodies toward donor mismatched antigens by Luminex multiplex bead array. Additional therapy included high-dose IVIg and plasma exchange. The renal function improved significantly. Furthermore, the donor-specific antibody strength decreased after combined plasmapheresis and IVIG therapy. These cases highlight the importance of donor-specific antibody detection by sensitive solid phase assays in the context of C4d-negative ABMR.
Discussion
Sensitive solid-phase platform allows for better diagnosis of ABMR after renal transplantation by identifying donor-specific anti-HLA antibodies. This is valuable for the clinical transplant team, especially in cases of inconclusive histopathology and C4d-negative histology. The routine monitoring of DSA in the post-transplant setting is a predictor of progression of antibody mediated rejection independent of C4d status (Case 2). These two cases provide an important message for the Indian population; where DSA (SAB) is not routinely measured at the time of transplant biopsy and where C4d staining alone has until recently been the gold standard for the diagnosis of ABMR. At our center (Sanjay Gandhi Post Graduate Institute of Medical Sciences), living related renal transplant recipients with negative pre transplant CDC crossmatch were evaluated by solid phase cross match (SPC) after transplantation. 21.5% recipients had DSA by SPC and those who were positive for HLA class II antibodies had significant association with ABMR. Solid phase crossmatch (SPC) testing performed with donor lysate on Luminex platform could sever as an estimate for diagnosis of rejection episodes. SAB is gold standard for the diagnosis of ABMR (Figs. 1 and 2).
DSA with single or multiple antigen beads is costly (particularly for individual patients). Solid phase crossmatch (SPC) testing is less expensive than SAB assay. Donor-specific antibody testing by SPC costs Rs. 2800 per test and by SAB assay costs 25,000 per test.
Solid phase crossmatch assay by Luminex can also be used for post-transplant routine DSA monitoring (economical for Indian population, although this test has limitations for the detection of HLA antibodies).
The presence of pre-transplant antibodies directed against donor antigens (HLA) called donor-specific antibodies (DSA) is strongly associated with hyper acute and acute rejection. [2] [3] [4] Production of de novo DSA after transplant is indicative of the antibody-mediated rejection (AMR). 5 The HLA-DSA monitoring is an important tool for rejection risk assessment in kidney transplant recipients. 6,7
Complement dependant cytotoxicity (CDC) cross match
This test was first standardized by Terasaki in 1960s. 8 It is used to detect the donor-specific antibodies directed against the recipient. Patel and Terasaki developed the CDC cross match for pretransplant donor recipient evalua- i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 1 0 ( 2 0 1 6 ) 1 5 -2 1
tion. If the result of the CDC cross match is positive, then transplantation with that donor is not advised. 9 CDC detects complement dependent anti-HLA specific antibodies. 8 CDC test is based on donor lymphocytotoxicity testing mediated by rabbit complement. It is performed by incubating recipient serum with donor lymphocytes and checking for donor lymphocytotoxicity after adding rabbit complement. Donor T and B lymphocytes are added to the recipient serum in the presence of complement, if donor cells are lysed then CDC is taken as positive and if they is no lysis then CDC is considered negative. CDC has limitation like a possibility of complement fixing antibodies which can result in donor lympho cytotoxicity in absence of donor-specific anti-HLA antibody.
Antibodies are most commonly directed against human leukocyte antigen (HLA)/major-histocompatibility-complex (MHC) class I and II antigens. 10 
3.2.

Panel reactive antibody (PRA)
This test involves screening serum of a prospective recipient against a panel of cells as targets for anti-HLA antibodies. Reactivity is expressed as percent positivity. Donor-specific anti-HLA antibodies are an indicator of donor-specific sensitization which could trigger rejection. 3 Degree of broad anti-HLA sensitization can be measured by PRA. The recipient serum's reaction with the screening panel of cells and the percentage of panel of target cells that react is termed as PRA percent (%). PRA measurement is an indicator of broad sensitization and immune reactivity of a recipient. Donor-specific antibody (DSA) is more specific in detecting sensitization against a particular donor. Flow cross match and Luminex based DSA tests are solidphase assays (SPAs) which have increased sensitivity and specificity allowing for better interpretation of impact of development of DSA in kidney transplant recipients. 11 
3.3.
The flow cross match (FCXM)
Flow cross match serves as a sensitive cross match test for the detection of DSA against recipient. 12 A positive FCXM picks up low level of DSA, which may not be clinically relevant. Many laboratories perform both CDC and FCXM assays before transplant especially in sensitized recipients and second transplants.
Single antigen bead (SAB) assay
In SAB test, each bead detects antibody directed against a single HLA antigen. Median fluorescence intensity (MFI) values of SAB assay semi-quantitatively estimate the intensity of each anti-HLA antibody present and helps in detecting various significant anti-HLA antibodies in recipient. Each micro particle is coated with a single HLA molecule utilizing recombinant technology. Multiplex bead antibody assay systems for anti-HLA antibodies use a solid phase platform. Panel contains all of the most frequently observed HLA alleles (97 class I and 91 class II alleles). Assay beads are mixed with recipient serum. Virtual cross match is a SAB assay which is based on donor tissue typing and recipient anti-HLA antibody compatibility. It is also important to keep in mind the limitation of solid phase assays as the beads could be coated with HLA molecule which could get altered during recombinant processing. 13 DSA screening tests tend to identify anti-HLA antibodies for class I and class II and their titer. After transplant if donor-specific antibodies develop then the risk for AMR increases. To standardize results, labs need to identify cut off (MFI) values for Luminex based solid phase tests which would need to be compared with traditional CDC and flow cross match results. 14 DSA monitoring post transplant can allow for timely detection of antibodies and provide additional tool to individualize approach to anti-rejection treatment, as well as optimize successful outcome. 6, 15, 16 It is important to note that not all DSAs fix complement or cause ABMR and not all episodes of acute graft injury with capillary inflammation and C4d deposition are associated with DSAs being detected with standard assays. Majority of patients with DSA maintain normal kidney function for years and have long-term outcomes similar to non sensitized patients. [17] [18] [19] Currently available HLA antibody tests are qualitative and have not been cleared by the US Food and Drug Administration (FDA) for quantitative measurements. This is an important limitation of HLA antibody test systems. 20 Research is needed for risk stratification strategies on the basis of semi quantitative measures of DSA and calculated panel reactive antibody (PRA), immunoglobulin-G subclasses of anti-HLA antibodies, and C1q complement-fixing DSA. [21] [22] [23] Recently Transplantation Society has published consensus guidelines for the testing of HLA and non-HLA antibodies for clinical management of transplant recipients. 24 
C4d staining and ABMR
Sensitivity of C4d is low and its deposition is dependent on density of peritubular capillaries (PTCs). C4d-negative ABMR has been reported in 55% of graft biopsies with evidence of capillary inflammation. 25 Chronic ABMR in 60-63% of biopsies has been reported to be C4d negative 1,26 there is need for including new biomarkers of endothelial and capillary injury for ABMR diagnosis. DSA is one such biomarker with status equivalent to rejection. This has been incorporated into new Banff 2013 diagnostic criteria ( Table 2) . 27 
3.6.
Interpretation of DSA by SAB assays
Median fluorescence intensity (MFI) values of SAB assay quantifies the intensity of each anti-HLA antibody present and helps in detecting significant DSAs in recipient. Each micro particle is coated with a single HLA molecule utilizing recombinant technology. At our center an MFI of 1000 has been used as a cut off to interpret post transplant DSA as positive, based on rejection episodes, flow cross-match report and transplant biopsy report of ABMR. Some centers use higher cut-off of 1500 or 2000 MFI to diagnose positive DSA. The advantages of SAB assays are the sensitivity and specificity of the results obtained. When using single antigen bead assays, for each antibody detected, mean fluorescence intensity (MFI) value is obtained, which provides a measure of the strength each antibody. Solid phase assays by Luminex for the desensitization protocols help in identification of specificities of donor-specific anti-HLA antibody. HLA antibody testing by the solid phase Luminex bead based assays is important for success in achieving desensitization in HLA-antibody incompatible transplantation. Pretransplant CDC cross match along with pre and post transplant anti-HLA antibody testing are very important to reduce the renal allograft rejection.
Single antigen bead assays have very low probability of giving false positive results. In solid-phase assays rarely disconnect can occur in specificities of anti-HLA antibody detected. This could be due to alterations in SAB HLA molecule during bead creation by biotechnology. All assays based on micro particles coated HLA antigens beads are not giving same information, as the beads themselves, as well as the analytical platforms used to assess them, are not equivalent. But all solid-phase assays broadly correlate well with each other. 28 
Treatment of antibody mediated rejection (ABMR)
The primary aims of therapeutic modalities for ABMR are to remove existing donor-specific antibodies and inhibit their redevelopment. The management of ABMR is associated with poorer outcomes compared with traditional anti-T cell rejection therapy for acute cell-mediated rejection. 29 There are only five small randomized and eight non-RCTs in this area. 30 Of various reports, benefit was found in five studies evaluating plasmapheresis or immunoadsorption. Small, nonrandomized studies have suggested benefit of rituximab or bortezomib for abrogation of DSA. 30 An evaluation of patients in a randomized trial of kidney allograft recipients suggests that immunoadsorption (received by five patients and compared with the outcomes of five controls) was effective in reversing severe C4d-positive ABMR. 31 None of the randomized controlled studies support the benefits of IVIG in acute ABMR, despite its common use. Only one randomized controlled study has found plasmapheresis to be beneficial, while two controlled studies found no benefit 32, 33 and one found potential harm, 34 indicating that the role of plasmapheresis for the treatment of acute ABMR remains under debate. Few nonrandomized studies support role for rituximab, bortezomib, plasmapheresis and IVIG. The relative importance of various therapies is difficult to assess because treatment strategies were not standardized, doses and frequencies were not similar, and the specific drugs were combined with variety of other agents.
One-year results were recently reported from a phase III, multicenter, randomized, placebo-controlled trial (RITUX ERAH) that examined the effect of rituximab (combined with plasmapheresis, IVIG, corticosteroids, tacrolimus and mycophenolate mofetil). On a composite analysis of graft loss or absence of improvement of renal function at day 12, in patients with biopsy-proven acute ABMR, there was no advantage of rituximab over control for the graft loss or renal function outcome. 35 Eculizumab was recently used for the treatment of multidrug-resistant ABMR, 36 but there are no randomized controlled studies to confirm the efficacy of this expensive drug. The Kidney Disease: Improving Global Outcomes Transplant Work Group recommends the use of corticosteroids, plasmapheresis, IVIG, anti-CD20 antibodies and lymphocyte-depleting antibodies alone or in combination. 37 In these two cases, we used plasmapheresis (5 exchanges) and low dose intravenous immunoglobulin (IV IG) in dose of 150 mg per kg body weight after each session of plasmapheresis (involving removal of 2.5 blood volume equivalent plasma per session).
Rituximab and bortozemab have also been used in clonal deletion and desensitization protocols to improve renal allograft outcomes. [38] [39] [40] 
Conclusions
Early detection and identification of donor-specific anti-HLA antibody with sensitive solid-phase platforms could allow better diagnosis of ABMR or mixed forms of allograft rejection in renal transplantation.
